Business
-
Armata Pharmaceuticals announced details of an additional secured credit agreement with Innoviva Strategic Opportunities, the company’s largest shareholder. Armata said that it will pay interest at a 14% annual rate on the $10 million loan… Read more . . .
-
Emergent BioSolutions and Swiss biotech Rocketvax have announced that Emergent will make a strategic investment in Rocketvax parent company Swiss Rockets and will take over manufacturing and commercialization activities for 4 of Rocketvax’s intranasal vaccine candidates.… Read more . . .
-
Altamira Therapeutics said that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent covering the formulation of Bentrio bentonite-based nasal spray. Bentrio received 510(k) clearance in… Read more . . .
-
According to DPI developer Iconovo, the company has received a grant worth SEK 670,000 from the EU’s Innowwide initiative, which encourages small and medium-sized EU companies to enter international markets. The grant will fund a market study… Read more . . .
-
According to Silo Pharma, the US Patent and Trademark Office (USPTO) has indicated that it will issue a new patent on March 4, 2025 that will provide protection for Silo’s SPC-15 intranasal ketamine. The company… Read more . . .
-
Tiziana Life Sciences announced that it has contracted with CDMO Renaissance Lakewood for development services related to Tiziana’s intranasal foralumab anti-CD3 monoclonal antibody. According to Tiziana, the project includes optimization of the formulation and development… Read more . . .
-
Kyorin Pharmaceutical is paying an undisclosed fee for the option to license Japanese development and marketing rights to Cyrano Therapeutics’ CYR intranasal theophylline for the treatment of loss of smell, the companies said. A Phase… Read more . . .
-
The Coalition for Epidemic Preparedness Innovations (CEPI) is providing $5 million to inhaled RNA developer Ethris for development of spray-dried RNA vaccines for nasal delivery. Ethris said that it plans to focus initially on a… Read more . . .
-
According to ENA Respiratory, California-based non-profit organization Flu Lab is providing a $5 million investment to support a Phase 2 proof of concept study of the company’s INNA-051 intranasal dry powder TLR2/6 agonist for the treatment… Read more . . .
-
California-based startup Miist Therapeutics, which calls itself “a physics-based developer of inhaled medicines,” announced that it has raised $7 million in seed funding and is developing 2 candidates: MST-01 for smoking cessation and MST-02 for… Read more . . .
Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK



